Introduction {#S1}
============

Non-small cell lung cancer (NSCLC) has served as a model for genotype-directed targeted cancer therapy. NSCLC patients whose tumors harbor activating kinase domain mutations in the epidermal growth factor receptor (*EGFR*) often initially respond to treatment with an EGFR tyrosine kinase inhibitor (TKI) such as erlotinib.[@R1]--[@R4]However, acquired resistance to *EGFR* TKI treatment invariably develops.[@R5],[@R6] There is no effective therapy for patients who develop such resistance. Work by our group and others has shown that resistance to *EGFR* TKI treatment can occur through a secondary resistance mutation in *EGFR* (T790M), activation of the *MET* kinase, and activation of the NF-kB pathway.[@R7]--[@R11]. [@R12]The mechanisms underlying acquired resistance to *EGFR* TKI treatment are unknown in over 40% of *EGFR*-mutant NSCLC patients.

Recent studies indicate that multiple resistance mechanisms may operate within an individual tumor to promote *EGFR* TKI acquired resistance in NSCLC patients. For example, the *EGFR* T790M resistance mutation and activation of *MET* can co-occur in some *EGFR*-mutant NSCLCs with acquired resistance to *EGFR* TKI treatment.[@R13][@R12] Furthermore, recent evidence suggests that the acquisition of *EGFR* TKI resistance in *EGFR*-mutant NSCLCs may be associated not only with genotypic alterations but also histological changes that occur during adaptation to therapy.[@R14]

By studying human *EGFR*-mutant NSCLC tumor models and clinical specimens we aimed to: 1) identify novel mechanisms of acquired resistance to *EGFR* TKI treatment, and 2) further clarify the extent to which distinct and co-existent genotypic and histological changes promote the acquisition of *EGFR* TKI treatment resistance in NSCLC patients.

Results {#S2}
=======

*AXL* promotes resistance *in vivo* and *in vitro* {#S3}
--------------------------------------------------

To identify novel mechanisms of acquired resistance to *EGFR* TKI treatment, our 3 groups independently established new *in vivo* and *in vitro* (n=5) models of acquired resistance to the *EGFR* TKI erlotinib using *EGFR* exon 19 deletion mutant (delE746-A750) HCC827 human NSCLC cells. HCC827 cells are initially sensitive to erlotinib treatment (*in vitro* IC~50~ \~5nM) and we and others have used them to develop *in vitro* models of *EGFR* TKI acquired resistance in studies that have led to the identification of clinically relevant mechanisms of *EGFR* TKI resistance.[@R10],[@R11] To establish the *in vivo* model, cohorts of 5 mice (2 tumors/mouse) with established HCC827 tumors were treated with vehicle or 4 escalating doses of erlotinib(from 6.25 mg/kg/day to 50 mg/kg/day) over \~ 5 months to derive erlotinib-resistant tumors. Erlotinib treatment of HCC827 xenograft tumors (10 tumors/dose, daily treatment) resulted in an initial dose-dependent decrease in tumor volume and the subsequent development of acquired resistance (\>25% re-growth from max reduction) after 6--10 weeks of treatment in each tumor ([Figure 1a](#F1){ref-type="fig"}, [Table 1](#T1){ref-type="table"}).Sequencing of *EGFR* in each erlotinib resistant tumor showed that none harbored the *EGFR* T790M mutation nor other secondary mutations in *EGFR* associated with erlotinib resistance (D761Y, L474S, T854A) (data not shown). To examine whether the erlotinib resistant tumors harbored increased expression of either known or potential novel drivers of resistance, we conducted microarray expression profiling of 17 xenograft tumors across each treatment group as well as 2 vehicle treated control tumors. We asked which genes were differentially regulated in the erlotinib resistant tumors compared to the control tumors (unpaired T-test, P\<0.05). The analysis showed that 21 genes were increased (≥1 log~2~ fold change) specifically in the erlotinib resistant tumors ([Supplementary Table 1](#SD2){ref-type="supplementary-material"}). Unexpectedly, we found that the receptor tyrosine kinase *AXL* was the most highly overexpressed gene in the tumors with acquired erlotinib resistance ([Supplementary Table 1](#SD2){ref-type="supplementary-material"}). Consistent with prior studies[@R9],[@R13], we also observed that *MET* was among the genes upregulated, although to a much lesser extent that *AXL*. We found increased mRNA expression of *MET* (≥1 log~2~ fold change) in 5/17 (29%) of the tumors with erlotinib acquired resistance ([Figure 1b](#F1){ref-type="fig"}, [Supplementary Table 2](#SD3){ref-type="supplementary-material"}). The analysis did not identify overexpression of IGF-1R, Ras, or *EGFR* in the erlotinib-resistant tumors ([Supplementary Tables 1](#SD2){ref-type="supplementary-material"}, [2](#SD3){ref-type="supplementary-material"}). Compared to control tumors, expression of *AXL* was increased (≥1 log~2~ fold change) in 15/17 (88%) of the tumors with erlotinib resistance ([Figure 1c](#F1){ref-type="fig"}, [Supplementary Table 2](#SD3){ref-type="supplementary-material"}). Moreover, we also found increased expression (≥ 1 log~2~ fold change) of *GAS6*, the ligand for *AXL*, in 8/17 (47%) of the tumors with erlotinib resistance ([Figure 1d](#F1){ref-type="fig"}, [Supplementary Table 2](#SD3){ref-type="supplementary-material"}). *AXL* was overexpressed in each tumor that had increased *MET* or *GAS6* levels. In 10 of the 15 tumors (66.6%) with *AXL* upregulation, *MET* overexpression was not observed. In each tumor in which *AXL* and *MET* were both increased *AXL* was overexpressed to a higher degree. *AXL* and *GAS6* overexpression was unique to treatment resistant tumors and was not the result of acute effects of erlotinib treatment as their levels were not increased in erlotinib-sensitive tumors harvested after 48h of erlotinib treatment ([Supplementary Figure 1](#SD1){ref-type="supplementary-material"}). aCGH analysis showed that neither *AXL* or *GAS6* was amplified and sequencing of *AXL* revealed that it was not mutated in the erlotinib resistant tumors (data not shown). Based on these findings and recent data demonstrating that *AXL* can promote cell growth in several cancer cell lines[@R15],[@R16], we hypothesized that *AXL* overexpression and activation may promote acquired resistance to erlotinib in *EGFR*-mutant NSCLCs.

*AXL* has been previously associated with EMT and recent studies suggest that therapeutic resistance may, in some cases, be associated with histological changes including EMT in NSCLCs.[@R14],[@R17],[@R18] We noted that the tumor xenografts with acquired erlotinib resistance harbored alterations in the expression level of several genes that are established biomarkers of EMT. For example, we found increased levels of *COL6A1* (a type IV collagen), *HMGA1* and *HMGA2* and decreased levels of keratin genes (including *KRT6A*, *KRT14*, *KRT5*) ([Supplementary Table 1](#SD2){ref-type="supplementary-material"}) in the tumors with acquired erlotinib resistance compared with the control tumors. We further examined whether the erlotinib resistant xenograft tumors exhibit molecular changes known to occur during EMT. Indeed, we found downregulation of E-cadherin (≥0.5 log~2~ fold change) in 8/15 (53%) ([Figure 1e](#F1){ref-type="fig"}, [Supplementary Table 2](#SD3){ref-type="supplementary-material"}), upregulation of *COL6A1* (≥1 log~2~ fold change) in 14/15 (93%) ([Figure 1f](#F1){ref-type="fig"}, [Supplementary Table 2](#SD3){ref-type="supplementary-material"}) and increased vimentin (≥1 log~2~ fold change) in 10/15 (66%) ([Supplementary Figure 2](#SD1){ref-type="supplementary-material"}) of the erlotinib-resistant tumors with *AXL* overexpression compared to the vehicle treated control tumors.

Consistent with the microarray data, we found increased levels of *AXL* and phosphorylated (p) *AXL* proteins in representative resistant HCC827 tumor xenografts at each dose of erlotinib compared with vehicle-treated tumors ([Figure 2a](#F2){ref-type="fig"}). We did not find alterations in the levels of *IGF-1R*, pIGF-1R, or *Ras* in the erlotinib resistant tumors ([Figure 2a](#F2){ref-type="fig"}). In contrast, we observed decreased levels of pEGFR, pErbB3, and pMET in response to erlotinib treatment both in sensitive tumors harvested at 48h of treatment ([Figure 2b](#F2){ref-type="fig"}) and in resistant tumors at each dose of erlotinib compared to vehicle treated tumors ([Figure 2a](#F2){ref-type="fig"}). Erlotinib treatment for 48h decreased pAKT, pERK, and pRelA and increased Parp cleavage in sensitive tumors (a marker of apoptosis) ([Figure 2b](#F2){ref-type="fig"}) but pAKT, pERK, pRelA levels were maintained in each tumor with acquired erlotinib resistance ([Figure 2a](#F2){ref-type="fig"}). Furthermore, we observed increased expression of the EMT marker vimentin in several erlotinib-resistant tumors ([Figure 2a](#F2){ref-type="fig"}). These data suggest that *AXL* upregulation may activate AKT, MAPK or NF-kB signaling to promote resistance to erlotinib treatment in *EGFR*-mutant NSCLCs perhaps in association with an EMT.

*AXL* inhibition restores erlotinib sensitivity {#S4}
-----------------------------------------------

To determine whether inhibition of *AXL* may restore erlotinib sensitivity *in vivo*, we took a genetic approach because the pharmacokinetics and specificity of currently available *AXL* inhibitors *in vivo* are suboptimal. We generated xenograft tumors in immunocompromised mice using either parental HCC827 cells or an erlotinib resistant subclone of HCC827 cells that we established, which we found to express increased levels of *AXL* (HCC827 subline "ER1", discussed further below). We transduced the *AXL*-overexpressing HCC827 ER1 cells with either a non-targeting shRNA or an shRNA targeting *AXL* prior to engraftment into the mice and then treated them with either vehicle or erlotinib (12.5 mg/kg/day). As expected, the parental HCC827 tumors were sensitive to erlotinib treatment whereas the *AXL*-overexpressing HCC827ER1 tumors transduced with the non-target shRNA were erlotinib-resistant ([Figure 2c](#F2){ref-type="fig"}). In contrast, knockdown of *AXL* restored sensitivity to erlotinib in the HCC827 ER1 tumors ([Figure 2c--d](#F2){ref-type="fig"}). The data show that *AXL* was required for erlotinib resistance in this *in vivo* model.

To further explore the role of *AXL* in *EGFR* TKI acquired resistance we next focused on the novel *in vitro* models of erlotinib acquired resistance that we generated in conjunction with the *in vivo* tumor xenograft models. Five erlotinib resistant HCC827 clonal sublines were established ("ER" 1--5) independently in 3 laboratories, each with an erlotinib IC~50~\> 10 µM, through prolonged (\>5 months) and continuous exposure to erlotinib ([Figure 3a](#F3){ref-type="fig"}). Each of these cell lines was also resistant to the irreversible *EGFR* kinase inhibitor BIBW2992 (afatinib) ([Supplementary Figure 3](#SD1){ref-type="supplementary-material"}). Thus resistance in these cellular models is unlikely a consequence of the secondary drug resistance mutation (T790M) in *EGFR* and is generalizable to distinct classes of *EGFR* TKIs. Indeed, the *EGFR* T790M resistance mutation was not detected by sequencing in any ER subline (data not shown). We sought to determine whether *AXL* or other genes previously implicated in *EGFR* TKI acquired resistance were upregulated in the HCC827 ER1-5 sublines compared to parental cells. To identify genes that were differentially regulated (threshold 3-fold change, FDR\<0.1) in the context of erlotinib acquired resistance, we profiled the ER1-3 sublines as compared to parental HCC827 cells by genome-wide microarrays ([Supplementary Table 3](#SD4){ref-type="supplementary-material"}) and validated our findings by Q RT PCR and western blots in all 5 sublines. First, we noted that expression of *EGFR*, *MET*, *IGF-1R*, pIGF-1R and *Ras* was unaltered in each ER subline ([Figure 3b](#F3){ref-type="fig"}). We did not detect activating mutations in *K-Ras* or *BRAF* by sequencing in the ER sublines (data not shown). Consistent with our findings in the erlotinib resistant tumor xenografts, we found significant upregulation of *AXL* and its ligand *GAS6* in each HCC827 ER subline compared to HCC827 parental cells ([Figure 3b](#F3){ref-type="fig"}, [Supplementary Table 3](#SD4){ref-type="supplementary-material"}, [Supplementary Figure 4](#SD1){ref-type="supplementary-material"}). We also found increased expression of vimentin and decreased expression of E-cadherin in each ER subline ([Figure 3b](#F3){ref-type="fig"},[Supplementary Figure 4](#SD1){ref-type="supplementary-material"}). Neither somatic mutations in nor genomic amplification of *AXL* were found by sequencing and aCGH (or FISH), respectively, in the HCC827 ER sublines (data not shown).

We next asked whether *AXL* overexpression and activation was necessary for erlotinib acquired resistance *in vitro* by genetically or pharmacologically inhibiting *AXL* in the HCC827 ER sublines. First we found that knockdown of *AXL* using an *AXL* siRNA had no effect on erlotinib sensitivity in parental HCC827 cells but restored erlotinib sensitivity in each ER subline ([Figure 3c](#F3){ref-type="fig"}). Interestingly, we found that knockdown of *GAS6* restored erlotinib sensitivity in the ER1 and ER2 sublines but not in the ER3, ER4 or ER5 sublines ([Figure 3c](#F3){ref-type="fig"}). This observation is reminiscent of recent data showing that upregulation of the *MET* ligand HGF can promote resistance to gefitinib treatment in some *EGFR* mutant NSCLC cells.[@R10] Because we observed residual, albeit diminished, levels of p*MET* in some of the ER sublines, we asked whether *MET* knockdown by siRNA could restore erlotinib sensitivity in this system. We found that knockdown of *MET* did not significantly affect erlotinib sensitivity either in parental or HCC827 ER1 cells or further enhance the effects of *AXL* knockdown on erlotinib sensitivity in ER1 cells ([Supplementary Figure 5](#SD1){ref-type="supplementary-material"}).

Treatment with a monoclonal antibody against *AXL* was recently shown to sensitize NSCLC cell lines that express wild type (WT) *EGFR* to erlotinib.[@R19] Thus we asked whether knockdown of *AXL* by siRNA enhances erlotinib sensitivity in 5 NSCLC cell lines with WT *EGFR* (A549, H460, H1573, H2009, Calu-1). We found that *AXL* knockdown had no effect on erlotinib sensitivity in these cell lines ([Supplementary Figure 6](#SD1){ref-type="supplementary-material"}). Our data suggest that inhibition of *AXL* enhances erlotinib sensitivity specifically in the context of NSCLCs with *EGFR* kinase domain activating mutations in cells with acquired *EGFR* TKI resistance.

Next we sought to validate our genetic findings using 2 commercially available small molecule inhibitors of *AXL*, MP-470 and XL-880.[@R15] As expected, treatment with MP-470 (1 µM) or XL-880 (1 µM) alone did not significantly affect the viability of HCC827 parental or ER cells ([Supplementary Figure 7](#SD1){ref-type="supplementary-material"}). In contrast, we found that treatment with MP-470 (1 µM) or XL-880 (1 µM), restored sensitivity to concurrent erlotinib treatment in each ER subline ([Figure 3d](#F3){ref-type="fig"}). To determine whether treatment with an *AXL* inhibitor is synergistic with concurrent erlotinib treatment we conducted combination index (CI) analysis in 2 of the ER sublines (ER1 and ER4). We found that treatment with either MP470 or XL880, but not the *MET* inhibitor PHA665752, was synergistic with concurrent erlotinib treatment ([Supplementary Figure 8](#SD1){ref-type="supplementary-material"}). Together, the genetic and pharmacologic data show that *AXL* is required for acquired erlotinib resistance in this system.

We aimed to determine which signaling events downstream of *AXL* might promote acquired erlotinib resistance in *EGFR* mutant NSCLCs. Because *AXL* has been shown to activate the MAPK, AKT and NF-kB pathways and regulate apoptosis in some cancer cell lines[@R15],[@R16], we examined activation of these pathways in HCC827 parental or ER cell lines treated with a non-targeting or *AXL* siRNA and either vehicle or erlotinib (100 nM). As expected, we found that erlotinib treatment decreased pERK, pAKT and pRelA (a marker of NF-kB signaling) and increased Parp cleavage (a marker of apoptosis) in parental HCC827 cells ([Figure 3e](#F3){ref-type="fig"}). *AXL* siRNA treatment had no effect on these pathways in parental HCC827 cells ([Figure 3e](#F3){ref-type="fig"}). Erlotinib treatment decreased p*EGFR* both in parental HCC827 cells and in the ER1 and ER2 sublines ([Figure 3e](#F3){ref-type="fig"}). This observation is consistent with our finding that the ER sublines do not harbor a secondary resistance mutation in *EGFR* that would abrogate the ability of erlotinib to inhibit *EGFR*. In contrast, erlotinib treatment decreased pERK, pAKT and pRelA and increased the levels of cleaved Parp only upon *AXL* knockdown in the ER1 and ER2 cell lines ([Figure 3e](#F3){ref-type="fig"}). Similar results were observed in HCC827 ER3, ER4 and ER5 sublines ([Supplementary Figure 9](#SD1){ref-type="supplementary-material"}).

We next sought to validate our genetic findings using pharmacologic inhibitors of *AXL*. As expected, erlotinib decreased pEGFR, pERK, pAKT, pRelA and increased the levels of cleaved Parp in parental HCC827 cells irrespective of concurrent treatment with MP-470 or XL-880 ([Figure 3f--g](#F3){ref-type="fig"}). In contrast, these effects of erlotinib treatment were observed only upon concurrent treatment with MP-470 ([Figure 3f](#F3){ref-type="fig"}) or XL-880 ([Figure 3g](#F3){ref-type="fig"}) in the HCC827 ER1 and ER2 cells. Similar results were observed in HCC827 ER3, ER4 and ER5 sublines treated with erlotinib and XL-880 either alone or in combination ([Supplementary Figure 9](#SD1){ref-type="supplementary-material"}). Together, the data suggest that *AXL* activation is necessary for acquired erlotinib resistance and that the MAPK, AKT and NF-kB pathways may, in part, mediate erlotinib resistance downstream of *AXL* in this system.

To determine whether *AXL* is upregulated in the setting of erlotinib acquired resistance in cells other than HCC827, we used the same erlotinib treatment protocol to establish 2 isogenic, erlotinib-resistant sublines (IC~50~\> 1 µM) derived from H3255 cells that express the *EGFR* L858R mutant commonly found in lung cancer patients and that are otherwise sensitive to erlotinib (IC~50~ \~15nM). Similar to HCC827 cells, we found (1) overexpression of *AXL* in the absence of *EGFR* T790M, pEGFR and increased pMET, (2) overexpression of the EMT marker vimentin, and (3) that inhibition of *AXL* by siRNA, MP-470 or XL880 restored sensitivity to concurrent erlotinib treatment in the H3255 ER sublines ([Supplementary Figure 10](#SD1){ref-type="supplementary-material"}). Together, these data show that *AXL* upregulation promotes erlotinib acquired resistance in the setting of EMT in *EGFR*-mutant NSCLC tumor models and that combined inhibition of *AXL* and *EGFR* overcomes acquired resistance to erlotinib in these models.

We next asked whether (1) forced expression of *AXL* is sufficient to induce erlotinib resistance and (2) whether *AXL* kinase activity is necessary for the induction of erlotinib resistance by *AXL*. To address these questions, we generated cDNA constructs that encode either wild type (WT) *AXL* or a kinase-impaired mutant of *AXL* in which a key conserved lysine within the kinase domain was changed to arginine (K567R). Transient overexpression of WT *AXL*, but not *AXL* KD (K567R), in HCC827 cells increased the levels of p*AXL* and the IC~50~ for XL880 ([Supplementary Figure 11](#SD1){ref-type="supplementary-material"}, [Figure 3h--i](#F3){ref-type="fig"}), suggesting that the K567R impairs *AXL* kinase function. Overexpression of WT *AXL*, but not kinase impaired *AXL* KD (K567R), induced resistance to erlotinib in HCC827 cells that was reversed upon treatment with XL-880 (1 µM) ([Figure 3h--i](#F3){ref-type="fig"}). In addition, we found that introduction of WT *AXL* was sufficient to induce partial resistance to erlotinib in PC9 cells that express an *EGFR* exon 19-deletion mutant and are otherwise erlotinib-sensitive (IC~50~\~25 nM) ([Supplementary Figure 12](#SD1){ref-type="supplementary-material"}). Together, the data indicate that *AXL* kinase activation is necessary and sufficient to promote erlotinib resistance in these *EGFR* mutant NSCLC models.

To confirm that treatment with an *AXL* inhibitor restores erlotinib sensitivity via inhibition of *AXL*, and is not a consequence of an "off-target" effect of drug treatment, we identified the "gatekeeper" residue within the *AXL* kinase domain based by structural modeling of the co-crystal of *MET* bound to XL880 and of the location of the T790M gatekeeper residue in *EGFR* [@R20],[@R21] ([Supplementary Figure 13](#SD1){ref-type="supplementary-material"}). The analysis indicated that an L620M mutation in *AXL* would be expected to result in steric clash with XL-880 and would block the ability of XL-880 to inhibit *AXL*. Thus we generated a cDNA encoding this gatekeeper mutant of *AXL* (L620M) and introduced it into HCC827 cells to determine if expression of it blocks the ability of XL-880 to restore erlotinib sensitivity in the setting of *AXL* overexpression. Expression of *AXL* L620M significantly increased the IC~50~ for XL-880 ([Supplementary Figure 11](#SD1){ref-type="supplementary-material"}) and blocked the ability of XL880 to decrease p*AXL* in HCC827 cells ([Figure 3i](#F3){ref-type="fig"}). In contrast to overexpression of WT *AXL*, we found that expression of *AXL* L620M abrogated the ability of XL-880 (1 µM) to restore erlotinib sensitivity in HCC827 cells ([Figure 3h--i](#F3){ref-type="fig"}). The data indicate that treatment with the *AXL* inhibitor XL880 restores erlotinib sensitivity by inhibiting *AXL* kinase activation in these *EGFR* mutant NSCLC models.

*AXL*-mediated resistance may occur with an EMT {#S5}
-----------------------------------------------

We observed an association between *AXL* overexpression and markers of EMT, including increased expression of vimentin, in several models of acquired erlotinib resistance. Recent data indicate that vimentin can promote EMT via epigenetic regulation of genes that are critical for EMT in breast cancer cells.[@R17] Thus we sought to determine whether vimentin overexpression was necessary for *AXL* overexpression and erlotinib resistance in HCC827 cells. We found that knockdown of vimentin by both pooled and 4 individual siRNAs decreased, but did not completely abolish, *AXL* expression ([Figure 4a](#F4){ref-type="fig"}). Vimentin knockdown and concomitant downregulation of *AXL* enhanced erlotinib sensitivity in HCC827 ER3 cells ([Figure 4b](#F4){ref-type="fig"}). Because vimentin has been shown to promote migration and adhesion in cells that have undergone an EMT[@R17],[@R22], we examined whether HCC827 ER cells exhibited increased migration and adhesion. We found that HCC827 cells with acquired erlotinib resistance (ER3) exhibit increased migration and adhesion compared to parental HCC827 cells ([Figure 4c--d](#F4){ref-type="fig"}). We also found that knockdown of vimentin, *AXL*, or treatment with XL880 inhibited migration and adhesion in HCC827 ER3 cells but had no effect in parental HCC827 cells ([Figure 4c--d](#F4){ref-type="fig"}). Together, the data support a possible role for an EMT that is marked by vimentin overexpression in the development of acquired *EGFR* TKI resistance that is driven by *AXL* in this model of human *EGFR* mutant lung cancer.

*AXL* is upregulated in patients with acquired resistance {#S6}
---------------------------------------------------------

Based on the preclinical data, we hypothesized that upregulation of *AXL* may promote acquired resistance to *EGFR* TKI treatment in *EGFR*-mutant NSCLC patients. To test this hypothesis and to clinically validate our preclinical findings, we measured the expression of *AXL* by IHC (immunohistochemistry) in 35 matched *EGFR*-mutant NSCLC specimens obtained from patients both prior to treatment with the *EGFR* TKIs erlotinib or gefitinib and upon the development of *EGFR* TKI acquired resistance. In cases where enough material was available for additional studies, we also examined the specimens for *GAS6* and vimentin (as a marker for EMT) expression by IHC (scoring system shown in [Supplementary Figure 14](#SD1){ref-type="supplementary-material"}), *EGFR* T790M by sequencing, and *MET* amplification by FISH. All patients in the cohort we analyzed had either an exon 19 deletion mutation or an exon 21 point mutation (L858R) in *EGFR*, were treated with either erlotinib or gefitinib and *MET* the established clinical definition of *EGFR* TKI acquired resistance ([Table 2](#T2){ref-type="table"}).[@R23] The clinical sample set that we analyzed harbored the full spectrum of major alterations known to occur in *EGFR* mutant lung cancer patients with acquired *EGFR* TKI resistance.[@R9],[@R12],[@R13],[@R14] Indeed, we detected the *EGFR* T790M mutation in 8/28 (29%) and *MET* amplification in 6/31 (19%) of the resistant specimens examined ([Tables 2](#T2){ref-type="table"}--[3](#T3){ref-type="table"} and [Figure 5a, b](#F5){ref-type="fig"}). As compared to the pre-treatment specimen, we detected increased expression (an increase by 2+ or greater) of *AXL* in 7/35 (20%) and *GAS6* in 7/28 (25%), and vimentin in 2/10 (20%) of the *EGFR* TKI resistant specimens evaluated ([Tables 2](#T2){ref-type="table"}--[3](#T3){ref-type="table"} and [Figure 5a--b](#F5){ref-type="fig"}). In 3 cases (\#13,14,15) in which *AXL* was expressed at the same level in the baseline and matched resistance specimen we detected increased *GAS6* specifically in the resistant specimen ([Tables 2](#T2){ref-type="table"}--[3](#T3){ref-type="table"}). This finding is consistent with the hypothesis that *GAS6* overexpression may promote *AXL* activation in the setting of *EGFR* TKI acquired resistance in some cases. This hypothesis is supported by our preclinical data showing that knockdown of *GAS6* can restore erlotinib sensitivity in some ER sublines that also overexpress *AXL* ([Figure 3c](#F3){ref-type="fig"}). In order to provide independent validation of our IHC findings of increased expression of *AXL* and *GAS6*, we performed Q-RT-PCR on a small cohort of *EGFR* T790M mutation negative *EGFR* mutant lung cancer specimens with acquired *EGFR* TKI resistance compared to matched baseline specimens (n=5). Using stringent cut-offs (threshold \>3 fold change in mRNA levels by Q RT PCR), we found increased *AXL* and *GAS6* mRNA levels upon resistance in 20% and 60%, respectively, of these specimens (data not shown). We did not find increased *AXL* or *GAS6* in the single specimen in which we detected increased *MET* expression (\>3 fold change in mRNA by Q RT PCR) in this small cohort (data not shown).

Our analysis of the clinical specimens indicates that some *EGFR* mutant NSCLCs with *EGFR* TKI acquired resistance can harbor multiple mechanisms of resistance. Consistent with prior studies,[@R13] we detected the *EGFR* T790M mutation in 50% of cases that also harbored *MET* amplification ([Tables 2](#T2){ref-type="table"}--[3](#T3){ref-type="table"}). Furthermore, we found co-occurrence of *EGFR* T790M and increased *AXL* and *GAS6* in a minority of cases ([Tables 2](#T2){ref-type="table"}--[3](#T3){ref-type="table"}). In contrast, we did not detect *MET* amplification in any resistance specimen that had increased *AXL* or *GAS6* expression ([Tables 2](#T2){ref-type="table"}--[3](#T3){ref-type="table"}). Coupled with the preclinical data, our findings suggest that activation of *AXL* and *MET* may be mutually exclusive mechanisms of acquired *EGFR* TKI resistance in NSCLCs.

Discussion {#S7}
==========

We have identified activation of the *AXL* kinase as a novel mechanism of acquired *EGFR* TKI resistance in *EGFR*-mutant NSCLCs through an integrated analysis of human *EGFR*-mutant NSCLC tumor models and one of the largest clinical cohorts of paired *EGFR*-mutant NSCLC specimens from *EGFR* TKI treated patients reported to date. Our analysis of the clinical specimens shows that *AXL* upregulation is the second most common mechanism of *EGFR* TKI acquired resistance (after *EGFR* T790M) in *EGFR*-mutant NSCLCs that has been validated using primary human data. The frequency of *EGFR* T790M in the *EGFR* TKI resistant samples in this cohort is lower than previously reported.[@R9],[@R12],[@R13],[@R14] Given that the sequencing assay we used to detect *EGFR* T790M is standard and validated, this likely represents either distinct biology of *EGFR* TKI resistance in the setting of *AXL* or *GAS6* upregulation or that there may be greater variability in the frequency of *EGFR* T790M in *EGFR* TKI resistant lung cancers than previously described. Importantly, we found upregulation of *AXL* in patients that developed resistance to both *EGFR* TKIs (erlotinib and gefitinib) that are clinically approved for use in NSCLC patients worldwide. Our findings are thus relevant to the vast majority of *EGFR*-mutant NSCLC patients treated with an *EGFR* TKI.

The data suggest that activation of *AXL* can occur through its overexpression as well as through upregulation of its ligand *GAS6* in the setting of *EGFR* TKI resistance in *EGFR*-mutant NSCLCs. This observation is consistent with recent work showing that both upregulation of *MET* and its ligand HGF can promote *EGFR* TKI resistance in some *EGFR*-mutant NSCLCs.[@R10] Our data showing that in some ER cell lines *GAS6* is not required for erlotinib resistance are consistent with earlier work demonstrating that *AXL* overexpression can promote downstream signaling and induce transformation in the absence of *GAS6* expression.[@R24] Further work will be necessary to fully elucidate the mechanisms by which *GAS6* might promote *EGFR* TKI resistance through activation of *AXL* and whether somatic alterations (amplifications, rearrangements, point mutations) in *AXL* or *GAS6* occur in human *EGFR*-mutant NSCLCs.

We found that in some cases *AXL* upregulation occurred in the context of an apparent EMT and that an EMT-associated transcriptional program involving upregulation of vimentin may, in part, drive *AXL* overexpression in *EGFR* mutant lung cancer cells with acquired *EGFR* TKI resistance. The data are consistent with prior studies in which vimentin upregulation was associated with *AXL* overexpression in breast cancer cells.[@R17] Although other mechanisms of *AXL* activation likely exist and will need to be investigated, our data are consistent with a model in which *AXL* may mediate acquired *EGFR* TKI resistance in the setting of an EMT in *EGFR*-mutant NSCLCs. *AXL*-overexpressing HCC827 ER cells exhibited increased migration and adhesion, properties associated with EMT and the *MET*astatic behavior of tumor cells. These findings in *EGFR*-mutant NSCLC cells with erlotinib acquired resistance are consistent with prior work showing that overexpression of *AXL* is associated with increased *MET*astasis and worse prognosis in several cancers.[@R15] Yet our studies uncover a distinct and specific role for *AXL* upregulation in acquired resistance to *EGFR* TKI treatment in *EGFR*-mutant NSCLC patients. Our data therefore extend current knowledge of the role of *AXL* as a general prognostic biomarker in human cancer and demonstrate for the first time that *AXL* is a biomarker of acquired resistance to *EGFR*-targeted therapy in NSCLC patients.

Our observation that multiple mechanisms of resistance may contribute to *EGFR* TKI treatment resistance in *EGFR* mutant NSCLC patients is consistent with other recent studies.[@R13],[@R14] Our data identifying *AXL* as a mechanism of *EGFR* TKI resistance enhance our understanding of tumor heterogeneity and the molecular mechanisms governing the evolution of resistance to molecularly targeted therapy in cancer patients. Further work will be necessary to determine the degree to which *AXL* activation may cooperate with other genetic and genomic alterations to induce resistance to *EGFR* inhibitors and other molecularly targeted therapies in lung and other cancers.

Our data show that the kinase activity of *AXL* is required for erlotinib resistance in *EGFR*-mutant NSCLC tumor models. This observation provides strong rationale for the development and testing of *AXL* kinase inhibitors for clinical use in *EGFR*-mutant NSCLC patients to either prevent or overcome *EGFR* TKI acquired resistance. The preclinical data also suggest that activation of multiple pathways including MAPK, AKT and NF-kB may promote *EGFR* TKI resistance downstream of *AXL* upregulation. This is consistent with prior work showing that *AXL* can drive the growth of cancer cells through activation of each of these pathways.[@R15],[@R16],[@R25] Further work will be necessary to determine which of these or other signaling pathways is most critical for *AXL*-driven *EGFR* TKI resistance in *EGFR*-mutant NSCLCs. Such studies may identify additional points for therapeutic intervention in the setting of *EGFR* TKI acquired resistance driven by *AXL* in *EGFR*-mutant NSCLC patients. Based on our data, we propose that inhibition of *AXL* signaling may enhance responses to *EGFR* TKI treatment in appropriately selected *EGFR*-mutant NSCLC patients.

Online Methods {#S8}
==============

Cell lines and reagents {#S9}
-----------------------

The human lung cancer cell lines were purchased from the American Type Culture Collection except for H3255, PC-9 cells which were generously provided by Susumu Kobayashi (Beth Israel Deaconess Medical Center, Boston, MA). Cells were grown in RPMI 1640 supplemented with 10% FBS and 1× Antibiotic/Antimycotic (Invitrogen) and were in the logarithmic growth phase at the initiation of all experiments. Erlotinib, XL880 (GSK1363089), PHA665752 and MP-470 were purchased from Selleck Chemicals (California, USA). Drugs were dissolved in DMSO at 10 mM and stored at −20°C. The final DMSO concentration in all experiments was \<0.1% in medium. All antibodies were purchased from Cell Signaling (Boston, MA) except the anti-*AXL* and anti-phospho-*AXL* and anti-*GAS6* antibodies, which were purchased from R&D Systems (Minneapolis, MN).

Establishment of erlotinib-resistant subclones {#S10}
----------------------------------------------

Cells were exposed to increasing concentrations of erlotinib every 3 weeks from 1, 3, 5, 7, and so on until 15 µM over a 5 months period. Single-cell cloning was performed by the use of cloning cylinders and erlotinib-resistant subclones were successfully expanded with 10% fetal bovine serum culture medium containing 1 µM erlotinib. The genetic identity of each subclone with the parental cells was verified by STR (short tandem repeat) analysis conducted at Johns Hopkins University (Baltimore, MD, USA) or the Korean Cell Line Bank (<http://cellbank.snu.ac.kr>) according to established protocols.

Cell growth and viability assays {#S11}
--------------------------------

Cells were seeded at a density of 3000 cells/well in 96-well plates in RPMI 1640 containing 10% FBS overnight, then treated with respective agents for an additional 3 days. Viable cell numbers were determined using CellTiterGLO or MTS assay kit, as indicated in the Figure legends, according to the manufacturer\'s protocols (Promega, Madison, WI, USA). Each assay consisted of 3 replicate wells and was repeated at least twice. Data were expressed as the percentage survival of control calculated from the absorbance, corrected for background.

Western blot analysis {#S12}
---------------------

Cells were serum starved overnight and whole cell lysates were prepared using 10% TCA lysis or RIPA buffer and clarified by centrifugation. Proteins were separated by 10% SDS-PAGE gel and transferred onto PVDF membranes (Invitrogen) for Western blot analysis. After primary antibody incubation overnight, washing and incubation with secondary antibodies, blots were developed with a chemiluminescence system (Pierce).

Gene expression profiling {#S13}
-------------------------

Gene expression microarray profiling was performed in triplicate following RNA isolation from cells or xenograft tumors using the Qiagen RNeasy kit according to the manufacturer's instructions using either Affy*MET*rix U1333 2.0 plus arrays (ER1, ER2) and analyzed as described previously[@R27][@R25] or Illumina Human HT12- v3 arrays (ER3) and analyzed by Illumina BeadStudio Gene Expression Module v3.2. Bioinformatics analysis was performed and genes were filtered to include genes with differential expression based on setting a threshold of 3 fold change and a false discovery rate (FDR) threshold at 0.1 for the comparison of gene expression in the ER cell lines to the parental (vehicle treated) cells.

Quantitative real time RT--PCR {#S14}
------------------------------

For the validation of genes identified by gene expression profiling, quantitative real-time RT--PCR was performed on RNA isolated from NSCLC cells. Total RNA was collected from cultured cells using PureLink Micro-to-Midi Total RNA Purification kit (Invitrogen, Carlsbad, CA, USA). cDNA was synthesized with SuperScript III reverse transcriptase with the use of oligo(dT) primers (Invitrogen) and RT-PCR was performed by using LightCycler with Syber green probes (Roche) using the following variables: denaturation at 95°C for 10 min, followed by 45 cycles of amplification(95°C 10 s, 60°C 10 s, and 72°C 15 s), and cooling to 40°C at a transition rate of 20°C/s. Levels of glyceraldehyde-3-phosphate dehydrogenase or actin expression were used as internal reference to normalize input cDNA. Ratios of level of each gene to as compared to reference standard were then calculated. Sequences for the primers used for *AXL* and *GAS6* Q RT-PCR are shown in Supplementary Table 4. Primers and probes used for *EGFR* and *MET* sequencing and FISH, respectively, were as previously published.[@R13],[@R28]

siRNA knockdown {#S15}
---------------

Knockdown of *AXL*, *MET* and vimentin was performed using specific single or pooled siRNAs, as indicated, targeting the indicated genes purchased from Dharmacon RNAi Technologies (Thermo Scientific, Rockford, IL). SiGENOME non-targeting siRNAs served as negative controls. Introduction of siRNA was performed with DharmaFect1 reagent according to the manufacturer's instructions. Efficiency of knockdown at different times or dose points was assessed by Q RT PCR or western blotting on cell lysates.

*AXL* cDNA and overexpression studies {#S16}
-------------------------------------

The *AXL* gene with an HA tag at the C-terminus was amplified by overlapping PCR using cDNA generated from ER3 cells and cloned into pcDNA3.1 (+) vector. Amino acid changes (K567R or L620M) were introduced using the Strategene QuickChange Mutagenesis Kit, according to the manufacturer's protocol. The accuracy of the constructs was confirmed by DNA sequencing. Cells were transfected with the *AXL*-expressing vectors or empty vector as a control by using FuGENE HD reagent according to the manufacturer\'s protocol (Roche Applied Sciences, Indianapolis, IN, USA). Stable HCC827 subclones resistant to the selection antibiotic, 500µg/ml G418 were generated 24 hours post-transfection. Empty-vector expressing HCC827 cells were generated as a control. *AXL* protein expression was detected by using anti-HA probe (Santa Cruz Biotechnology).

Migration and adhesion studies {#S17}
------------------------------

180,000 cells were plated onto 3.5 cm cell culture dishes. At 30 minutes, the dishes were washed and cells were fixed and stained for counting. Average cell numbers of 5 random 100× fields under light microscope are presented with ± SEM. Migration: 10,000 cells in 200 µl medium without FBS were placed in the upper chamber of transwells(6.5 mm diameter, 8 µm pore size polycarbonate membrane, Corning), and the lower chamber filled with 1 ml of medium with 10% FBS supplemented with or without the indicated drug treatments. After incubation for 16 hours, non-migrating cells were removed with cotton swabs, and the cells that migrated into the lower surface of the filters were stained with crystal violet. Cells were counted under a microscope, and triplicate results are expressed as means ± SEM.

shRNA knockdown {#S18}
---------------

For the shRNA experiments each retroviral and lentiviral shRNA was packaged in 293FT cells according to the manufacturer's instructions. Indicated cell lines were spin infected with 1 ug/ml polybrene and 48h after infection were selected with 2 µg/ml of puromycin for 48h. Target gene expression was measured by either Q RT PCR or western blot 48--72h later.

Tumorigenesis assays {#S19}
--------------------

Human lung cancer cells (as indicated) were injected subcutaneously into the flanks of CB17 SCID mice (Taconic). Tumor-bearing mice (tumor size 200--500 mm^3^) were randomized to treatment with vehicle (DMSO/CMC) or erlotinib HCL 12.5 mg/kg/day intraperitoneally. Tumor measurements were made on days indicated and expressed as described in the Figure legends. All animal experiments were performed in compliance with the guidelines of the Research Animal Resource Center of the Memorial Sloan-Kettering Cancer Center.

Combination index (CI) analysis {#S20}
-------------------------------

The combination effects were evaluated with the MTT assay at a 1:1 ratio (erlotinib (µM):XL880 (µM) and erlotinib (µM):PHA665752 (µM)) in HCC827ER cells. The fraction affected (Fa) (i.e., Fa of 0.25 is equivalent to 75% viable cells) and CI values processed using CalcuSyn software (Biosoft, Cambridge, UK).CI values of less than 1, 1, and greater than 1 were taken as synergism, additive effect, and antagonism, respectively.

Immunoprecipitation {#S21}
-------------------

For immunoprecipitation, 1 mg protein from total lysates was mixed with 1 µg of anti-*AXL* (Santa Cruz, CA), and incubated on ice for 2 h. Protein G Sepharose Fast Flow (GE Healthcare, Little Chalfont, Buckinghamshire, UK) was added to the mixture and incubated overnight at 4°. Immune complexes were pelleted by centrifugation at 3000 rpm for 5 min, washed twice with lysis buffer, and resuspended in 70 µl of SDS-PAGE sample buffer. Subsequently, immune complexes were probed with anti-*AXL* and phosphotyrosine antibodies(Santa Cruz, CA).

Sequencing of *AXL*, *EGFR*, K-Ras and B-Raf {#S22}
--------------------------------------------

Sequencing of full length of *AXL* and *EGFR* was performed by standard Methods using the primer sequences listed Supplementary Table 5. Sequencing of exon 2 of K-Ras and exons 11 and 15 of BRAF was performed on genomic DNA using validated primers and protocols.[@R13]

IHC on NSCLC clinical specimens {#S23}
-------------------------------

All specimens were acquired from patients under the auspices of IRB-approved clinical protocols at each hospital in which informed consent was obtained and were formalin-fixed, paraffin-embedded tumour tissues (FFPE), that were examined to ensure \>75% tumor infiltration, and stained with haematoxilin/eosin and assessed by a thoracic pathologist at MSKCC (New York, NY, USA), As an Medical Center (Seoul, South Korea), USP Dexeus University Institute (Barcelona, Spain). IHC was performed in the Core Research IHC Laboratory at each institution on FFPE sections, as previously described[@R29], using the indicated antibodies: Human *AXL* antigen - affinity-purified polyclonal antibody, R&D systems, catalog \#AF154*AXL* ; Human *GAS6* - affinity-purified polyclonal antibody, R&D systems, catalog \#AB885, Human vimentin - affinity-purified polyclonal antibody, Cell Signaling Technologies, catalog \#3932. Expression was examined by standard immunohistochemistry using 4um thick sections of matched, paired specimens. Deparaffinized tissue sections were stained following the manufacturer's protocol at a dilution of 1:500 on a Ventana Dixcovery XT automated stainer. *EGFR* T790M mutation and *MET* amplification were analyzed using previously described sequencing and FISH protocols,[@R13] respectively, and vimentin expression by IHC using established *MET* hods and clinical scoring criteria.[@R26]
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![*AXL* is overexpressed in *EGFR*-mutant NSCLC tumor xenografts with acquired resistance to erlotinib\
a, Effects of a dose-response of erlotinib in HCC827 xenograft tumors in immunocompromised mice (n=10 tumors/treatment group). b--f, mRNA expression of indicated genes in HCC827 erlotinib resistant tumor xenografts (treated at the indicated erlotinib doses) relative to vehicle-treated control tumors. The number of tumors analyzed from each treatment cohort is indicated in parentheses. Data are expressed as the mean ± SEM of the fold change relative to the mean expression of the genes in 2 vehicle treated control xenograft tumors.](nihms382267f1){#F1}

![*AXL* overexpression is necessary for acquired resistance to erlotinib treatment in *EGFR*-mutant NSCLC tumors *in vivo*\
**a**, *AXL* and p*AXL* protein levels are increased in the absence of p*EGFR* and increased p*MET* in HCC827 tumors from each erlotinib treatment cohort compared with vehicle treated tumors. Tumors were harvested for analysis at the completion of the study for each treatment group (Vehicle: Day 45; 6.25 Erl: Day 60; 12.5 Erl: Day 110; 25 Erl: Day 110; 50 Erl: Day 100) **b**, Acute and transient treatment of HCC827 tumors with erlotinib (12.5 mg/kg/day) decreases pAKT, pERK, pRELa and increases the levels of cleaved Parp. **c**, Response of parental HCC827 xenograft tumors or HCC827 ER xenograft tumors (n= 10 tumors/group) transduced with a non-target shRNA or an shRNA targeting *AXL* to treatment with either vehicle or erlotinib (12.5 mg/kg/day). Tumor volumes are expressed as mean ± SEM. **d**, Validation of *AXL* knockdown and the effects of erlotinib treatment on p*EGFR* in representative tumor xenografts (c) by western blot analysis.](nihms382267f2){#F2}

###### *AXL* upregulation is necessary and sufficient for erlotinib acquired resistance in *EGFR* mutant NSCLC cellular models

**a**, HCC827 ER1-ER5 sublines are resistant to erlotinib treatment as measured by CellTiterGLO cell viability assay. Data are from 3 independent experiments and are expressed as percent of vehicle treated cells and mean ± SEM. **b**, Expression of *AXL* and *GAS6* in the ER sublines compared with parental HCC827 cells (data are from Western blot analysis). **c**, Erlotinib IC~50~ in HCC827 cell lines (as indicated) measured 48h after treatment with a non-targeting or *AXL* or *GAS6* siRNA. Erlotinib IC~50~ is shown in parentheses. Data are representative of 3 independent experiments. **d**, Erlotinib IC~50~ in HCC827 cell lines (as indicated) measured 48h after treatment with vehicle (control) or with MP-470 (1 µM) or XL-880 (1 µM) and erlotinib. Erlotinib IC~50~ is shown in parentheses. Data are representative of 3 independent experiments. **e**, Effects of treatment for 48h with a non-targeting (−) or *AXL* siRNA in parental or ER1 and ER2 cell lines in the absence and presence of erlotinib on the indicated biomarkers. Data represent 3 independent experiments. **f--g**, Effects of treatment for 48h with a vehicle or the indicated doses of (**f**) MP-470 or (**g**) XL-880 in parental or ER1 and ER2 cell lines in the absence and presence of erlotinib on the indicated biomarkers. Data represent 3 independent experiments. **h**,Erlotinib IC~50~ in HCC827 cells measured 5 days after transfection the cDNA constructs encoding the indicated proteins and treated with either vehicle (left) or with XL-880 (1 µM) and erlotinib. Erlotinib IC~50~ is shown in parentheses. Data are representative of 3 independent experiments. **i**, Western blot for the indicated proteins in lysates from cells transfected with the indicated cDNA constructs and treated with XL-880 (1 µM) for 3 hours prior to cell lysis (**h**).

![](nihms382267f3a)

![](nihms382267f3b)

![](nihms382267f3c)

###### *AXL*-mediated erlotinib resistance occurs in association with EMT in *EGFR*-mutant NSCLC cellular models

**a**, Effects of treatment with a non-targeting or the indicated vimentin siRNAs on *AXL* expression in HCC827 ER3 cells. **b**, Erlotinb IC~50~ in HCC827 parental or ER3 cells upon treatment with a non-targeting or the indicated vimentin siRNAs. Erlotinib IC~50~ is shown in parentheses. Data represent 3 independent experiments. **c**, Increased migration through a transwell chamber of ER3 compared to parental HCC827 cells in cells treated with a non-targeting or the indicated vimentin (VIM) or *AXL* siRNAs or XL-880 (1 µM); n=3, data expressed as mean ± SEM. **d**, Increased adherence to plastic of HCC827 ER3 cells compared to HCC827 parental cells in cells treated with a non-targeting or the indicated vimentin (VIM) or *AXL* siRNAs or XL-880 (1 µM). 5 100× microscopic fields per cell line were counted. n=3, data expressed as mean ± SEM. **e**, Western blot for the indicated proteins in lysates from cells transfected with the indicated siRNAs in (**c--d**).

![](nihms382267f4a)

![](nihms382267f4b)

![*AXL* upregulation occurs in human *EGFR*-mutant NSCLCs with *EGFR* TKI acquired resistance\
**a--b**, Representative expression of the indicated proteins by IHC in (**a**) case 7 and (**b**) case 9 shown in [Table 2](#T2){ref-type="table"}. IHC staining for *AXL* and *GAS6* was scored as shown in [Supplemental Figure 14](#SD1){ref-type="supplementary-material"}. Vimentin IHC staining was scored using an established, clinically validated protocol[@R26]and *EGFR* T790M and *MET* amplification were assessed by sequencing and FISH, respectively, using established assays. Scale bars indicate in (**a**) 100 µM and (**b**) 10 µM.](nihms382267f5){#F5}

###### Erlotinib treatment response in HCC827 tumor xenografts

Data from 10 tumors per treatment group are expressed as average tumor volume reduction, median time to maximum reduction, and median time to erlotinib resistance ± SEM.

  ----------------------------------------------------------------------------------------------
  Erlotinib Dose\   Maximum Volume Reduction\   Time to Maximum\    Median Time to Resistance\
  (mg/kg)           \                           \                   (weeks)
                    \                           Volume Reduction\   
                    (% change from baseline)    (weeks)             
  ----------------- --------------------------- ------------------- ----------------------------
  6.25              N/A                         N/A                 N/A

  12.5              −56                         4 ± 0.3             6 ± 0.5

  25                −69                         5 ± 0.2             8 ± 0.8

  50                −84                         4 ± 0.4             10 ± 1
  ----------------------------------------------------------------------------------------------

###### *AXL* is upregulated in human *EGFR* mutant NSCLC specimens from patients with acquired *EGFR* TKI resistance

Clinical characteristics and expression of the indicated biomarkers in the 35 paired *EGFR*-mutant NSCLC specimens obtained from patients both prior to treatment and upon acquired resistance to treatment with either erlotinib or gefitinib (Median PFS= 18 months, range 7--59). NA= not enough tissue available for analysis. ACC= adenocarcinoma. NSC= non-small cell carcinoma. SqCC= squamous cell carcinoma. VIM = vimentin.

  -----------------------------------------------------------------------------------
  ID   Age   Sex   Tumor\   *EGFR*\        TKI                            
                   type     mutation                                      
  ---- ----- ----- -------- ---------- --- ----- ---- ---- ---- ---- ---- -----------
  1    49    M     ACC      L858R      0   3     NA   NA   −    N    NA   gefitinib

  2    50    M     ACC      Del19      0   3     0    3    −    N    N    gefitinib

  3    80    M     ACC      Del19      0   3     0    3    \+   N    N    gefitinib

  4    64    F     ACC      L858R      1   3     NA   NA   −    N    N    gefitinib

  5    47    F     NSC      Del19      0   2     NA   NA   −    NA   N    gefitinib

  6    48    F     ACC      L858R      2   3     2    2    −    N    N    gefitinib

  7    59    F     NSC      Del19      0   3     1    0    \+   N    NA   erlotinib

  8    67    F     NSC      Del19      0   1     0    0    \+   N    NA   erlotinib

  9    74    M     ACC      Del19      1   3     0    3    −    N    Y    erlotinib

  10   49    F     ACC      L858R      2   3     2    3    −    N    N    gefinitib

  11   43    M     NSC      Del19      2   3     0    3    −    N    N    gefinitib

  12   56    F     NSC      Del19      1   1     0    2    −    N    N    erlotinib

  13   54    F     ACC      Del19      3   3     0    3    −    N    NA   gefitinib

  14   67    M     ACC      Del19      3   3     0    2    −    N    NA   gefitinib

  15   59    M     ACC      Del19      3   3     0    1    −    NA   Y    gefitinib

  16   50    F     ACC      Del19      0   0     NA   NA   NA   Y    NA   gefitinib

  17   76    F     ACC      Del19      0   0     3    3    NA   N    NA   gefitinib

  18   64    F     SqCC     Del19      0   0     0    0    \+   Y    NA   gefitinib

  19   66    F     ACC      L858R      0   0     1    0    −    N    NA   gefitinib

  20   54    F     ACC      Del19      0   0     0    0    −    N    NA   gefitinib

  21   67    F     ACC      L858R      0   0     NA   NA   NA   NA   NA   gefitinib

  22   73    F     ACC      L858R      0   0     3    3    −    N    NA   gefitinib

  23   58    M     ACC      Del19      0   0     NA   NA   \+   Y    NA   gefitinib

  24   73    F     ACC      L858R      0   0     2    2    \+   Y    NA   gefitinib

  25   62    F     ACC      Del19      0   0     3    3    NA   Y    NA   gefitinib

  26   77    M     ACC      L858R      0   0     NA   NA   NA   NA   NA   gefitinib

  27   72    F     ACC      Del19      0   0     2    3    −    N    NA   gefitinib

  28   51    F     ACC      L858R      0   0     0    0    −    N    NA   gefitinib

  29   67    M     ACC      L858R      0   0     3    3    \+   N    NA   gefitinib

  30   63    M     ACC      L858R      0   0     3    0    −    N    NA   gefitinib

  31   57    F     ACC      Del19      0   0     0    0    NA   N    NA   gefitinib

  32   71    F     ACC      Del19      0   0     0    0    NA   N    NA   gefitinib

  33   54    F     ACC      Del19      0   0     0    0    −    N    NA   gefitinib

  34   56    F     NSC      Del19      0   0     1    0    −    Y    NA   gefitinib

  35   54    F     NSC      Del19      0   0     0    0    \+   N    NA   gefitinib
  -----------------------------------------------------------------------------------

###### 

Summary of resistance biomarker scoring in the paired specimens analyzed in [Table 2](#T2){ref-type="table"}.

  -----------------------------------------------------------------
  Marker     \#\        \% of\      ConcurrentT790M   Concurrent\
             positive   evaluable                     *MET*
  ---------- ---------- ----------- ----------------- -------------
  *AXL*      (7/35)     20          2                 0

  *GAS6*     (7/28)     25          1                 0

  T790M      (8/28)     29          \-                3

  *MET*      (6/31)     19          3                 \-

  Vimentin   (2/10)     20          0                 0
  -----------------------------------------------------------------

[^1]: Equal contribution.
